Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects
Figure 6
Effect of BAY 85-3934, erythropoietin (EPO), and enalapril in the rat subtotal nephrectomy model.
Data are presented as means ± SEM. (A) Packed cell volume (PCV), (B) systolic blood pressure (SBP), and (C) prorenin following oral administration of BAY 85-3934 (2.5 mg/kg or 5 mg/kg once daily) or rhEPO (100 IU/kg s.c. twice weekly) for 5 weeks, compared with control and sham-operated animals (n = 4–6 animals per group). Efficacy of BAY 85-3934 sodium (80 ppm), enalapril (30 ppm), and a combination of both, administered in drinking water for 5 weeks, on (D) PCV, (E) SBP (at 4 weeks), and (F) prorenin (n = 9–10 animals per group). *p<0.05, **p<0.01, ***p<0.001; one-way ANOVA followed by Dunnett’s multiple comparison test to corresponding sham or control group for (A), (C), (D), and (E), and Bonferroni’s multiple comparison test to corresponding sham or control group for (B) and (F).